These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 26429330)
1. Role of galectin-3 in the pathogenesis of bladder transitional cell carcinoma. Zeinali M; Adelinik A; Papian S; Khorramdelazad H; Abedinzadeh M Hum Immunol; 2015 Oct; 76(10):770-4. PubMed ID: 26429330 [TBL] [Abstract][Full Text] [Related]
3. Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis. Packeiser EM; Hewicker-Trautwein M; Thiemeyer H; Mohr A; Junginger J; Schille JT; Murua Escobar H; Nolte I PLoS One; 2020; 15(3):e0230272. PubMed ID: 32168360 [TBL] [Abstract][Full Text] [Related]
4. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602 [TBL] [Abstract][Full Text] [Related]
5. galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Cindolo L; Benvenuto G; Salvatore P; Pero R; Salvatore G; Mirone V; Prezioso D; Altieri V; Bruni CB; Chiariotti L Int J Cancer; 1999 Feb; 84(1):39-43. PubMed ID: 9988230 [TBL] [Abstract][Full Text] [Related]
6. Gene-expression signature of adhesion/growth-regulatory tissue lectins (galectins) in transitional cell cancer and its prognostic relevance. Langbein S; Brade J; Badawi JK; Hatzinger M; Kaltner H; Lensch M; Specht K; André S; Brinck U; Alken P; Gabius HJ Histopathology; 2007 Nov; 51(5):681-90. PubMed ID: 17927590 [TBL] [Abstract][Full Text] [Related]
7. Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives. Bartolazzi A; Sciacchitano S; D'Alessandria C Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393868 [TBL] [Abstract][Full Text] [Related]
8. Role of Galectins in Tumors and in Clinical Immunotherapy. Chou FC; Chen HY; Kuo CC; Sytwu HK Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29389859 [TBL] [Abstract][Full Text] [Related]
9. Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3. Fang T; Liu DD; Ning HM; Dan Liu ; Sun JY; Huang XJ; Dong Y; Geng MY; Yun SF; Yan J; Huang RM Acta Pharmacol Sin; 2018 Dec; 39(12):1885-1893. PubMed ID: 29769742 [TBL] [Abstract][Full Text] [Related]
10. Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment. Hsieh HY; Jou YC; Tung CL; Tsai YS; Wang YH; Chi CL; Lin RI; Hung SK; Chuang YM; Wu SF; Li C; Shen CH; Chan MWY; Hsu CD Oncogene; 2018 Feb; 37(5):673-686. PubMed ID: 29035390 [TBL] [Abstract][Full Text] [Related]
11. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment. Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699 [TBL] [Abstract][Full Text] [Related]
12. miR-130b, an onco-miRNA in bladder cancer, is directly regulated by NF-κB and sustains NF-κB activation by decreasing Cylindromatosis expression. Cui X; Kong C; Zhu Y; Zeng Y; Zhang Z; Liu X; Zhan B; Piao C; Jiang Z Oncotarget; 2016 Jul; 7(30):48547-48561. PubMed ID: 27391066 [TBL] [Abstract][Full Text] [Related]
13. [One molecule, two faces. Epithelial loss of cell adhesion molecule CEACAM1 activates angiogenesis in bladder and prostate cancer]. Tilki D; Oliveira-Ferrer L; Kilic N; Friedrich MG; Stief CG; Ergun S Urologe A; 2007 Sep; 46(9):1128-34. PubMed ID: 17605118 [TBL] [Abstract][Full Text] [Related]
14. Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy? Rassy E; Assi T; Kattan J Future Oncol; 2019 Dec; 15(34):3877-3879. PubMed ID: 31729240 [No Abstract] [Full Text] [Related]
15. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881 [TBL] [Abstract][Full Text] [Related]
16. Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Canesin G; Gonzalez-Peramato P; Palou J; Urrutia M; Cordón-Cardo C; Sánchez-Carbayo M Tumour Biol; 2010 Aug; 31(4):277-85. PubMed ID: 20401558 [TBL] [Abstract][Full Text] [Related]
17. Expression of brain‑specific angiogenesis inhibitor‑1 and association with p53, microvessel density and vascular endothelial growth factor in the tissue of human bladder transitional cell carcinoma. Tian D; Hu H; Sun Y; Tang Y; Lei M; Liu L; Han R; Wu C Mol Med Rep; 2015 Sep; 12(3):4522-4529. PubMed ID: 26129954 [TBL] [Abstract][Full Text] [Related]
18. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer. Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of galectin-3 expression in urinary bladder carcinoma. Al-Maghrabi JA; Khabaz MN J Int Med Res; 2023 Feb; 51(2):3000605231153323. PubMed ID: 36748414 [TBL] [Abstract][Full Text] [Related]
20. Galectin-3 in angiogenesis and metastasis. Funasaka T; Raz A; Nangia-Makker P Glycobiology; 2014 Oct; 24(10):886-91. PubMed ID: 25138305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]